LUCA-15 maps to human 3p21.3, a region of the chromosome important to a number of cancers, including lung and breast (Kok et al., 1997) . Loss of heterozygosity (LOH) occurs at 3p21.3 in 100% of small cell lung carcinoma (SCLC) cell lines, 490% of non-SCLC cell lines, and 490% of primary lung cancers (Gazdar et al., 1994) , implying the existence of a lung cancer tumour suppressor gene in this region. Precise delineation of the deletions resulting in the LOH has been the focus of extensive study over the past 10 years (Daly et al., 1993; Imreh et al., 1997; Kashuba et al., 1995; Kholodnyuk et al., 1997; Kok et al., 1994; Sekido et al., 1998; Szeles et al., 1997; Todd et al., 1996; Wei et al., 1996; Yamakawa et al., 1993) , and evidence exists that LUCA-15 is included in a number, but not all, of these lesions Szeles et al., 1997; Timmer et al., 1999; . However, as cancers which involve the short arm of chromosome 3 progress, the number/extent of lesions appears to increase, complicating analysis of important tumour suppressor regions (Chung et al., 1995; Kok et al., 1997) . Any novel gene mapping to this region is therefore recognized as a putative tumour suppressor gene (Daigo et al., 1999; Frederick et al., 1998; Gray et al., 1995; Jackers et al., 1996; Jensen et al., 1998; Kashuba et al., 1997; Latif et al., 1997; Sekido et al., 1996; Shriver et al., 1998; Sithanandam et al., 1996; Timmer et al., 1999; Uchida et al., 1997) . Interestingly, in both primary cells and cell lines from breast cancers, a direct correlation has been shown between upregulation of LUCA-15 RNA (Clone H37: Accession No. AAF02422) and HER-2/neu oncogene overexpression, suggesting that LUCA-15 might in fact be an oncogene (Oh et al., 1999) .
LUCA-15 is ubiquitously expressed, but has no known function, although it has two RNP-1 RNA binding motifs, two zinc ®nger DNA binding motifs, two bipartite nuclear localization signals and a G-patch (a new conserved domain in eukaryotic RNA-processing proteins and type D retroviral polyproteins) (Aravind and Koonin, 1999) , suggesting a role for LUCA-15 in RNA splicing. Two additional pieces of evidence support a role for LUCA-15 in RNAprocessing. Firstly, it has been demonstrated that human LUCA-15 RNA binding domains are able to speci®cally bind poly(G) RNA tracts in vitro (Drabkin et al., 1999) . Secondly, the rat homologue of LUCA-15, the S1-1/RNA binding motif protein 10 (Accession No. BAA12144, Accession No. P70501) (54% identity over 814 aa), has been shown to preferentially bind homopolymer RNA in vitro (poly(G)=poly(U)4po-ly(C)4poly(A)), and associate with hnRNA in the nucleus (Inoue et al., 1996) . These data strongly suggest that LUCA-15 is an RNA-associating protein, and plays a role in RNA processing.
Similar sequence to LUCA-15 is found in the human RBM5 gene products (Accession No. NM_005778, No. XM_003261, No. AF103802 ) and the KIAA0122 novel gene product (Accession No. BAA09471), which all map to the LUCA-15 gene locus, and may therefore be LUCA-15 expression mutants/variants. LUCA-15 protein sequence also has striking homology to the Drosophila gene product CG4887 (Accession No. AAF51400) (31% identity over 852 aa) and a C. elegans protein (Accession No. AAC48191) (30% identity over 677 aa), neither of which has a known function.
Recently, splice variants from the LUCA-15 gene locus have been shown to function as regulators of apoptosis (Sutherland et al., 2000) , a fact which may have signi®cance in tumour regulation (Wyllie, 1997) . We have evidence that both alternative RNA splicing and antisense transcription occur at the LUCA-15 gene locus (Sutherland et al., 2000) . At least four RNA splice variants have been observed. One of these variants (Clone 26) (Accession No. AF107493), containing two introns and encoding a truncated protein with none of the consensus functional motifs found in the full-length LUCA-15 protein, has been shown to induce apoptosis in the absence of an apoptogenic stimulus, and signi®cantly enhance CD95-mediated apoptosis, when overexpressed in Jurkat T cells (Sutherland et al., 2000) . A cDNA fragment (Je2) (Accession No. AF107492), in the opposite transcriptional orientation to LUCA-15, maps to one of the introns of Clone 26, and was able to suppress CD95-mediated apoptosis when overexpressed in the Jurkat cells, suggesting antisense inhibition of the apoptosis inducing LUCA-15 splice variant. Since Clone 26 is able to induce apoptosis but is expressed in proliferating cultures, it was hypothesized that, as is observed for the apoptosis regulators Bcl-x L /Bcl-x S (Boise et al., 1993) , Ich-1 L /Ich-1 S (Wang et al., 1994) and C. elegans ced-4L/ced-4S (Shaham and Horvitz, 1996) , at least one of the alternative splice variants, containing functional motifs, inhibits apoptosis. As for ced-4, the balance of products would decide cell fate. The aim of this study, therefore, was to examine the functional role of the full length LUCA-15 gene in apoptosis. Figure 1 Selection of stably transfected LUCA-15 clones by functional analysis. LUCA-15 was directionally subcloned into pcDNA3 (Invitrogen) using the restriction endonucleases BamHI and XhoI. Plasmid pcDNA3 or pcDNA3.LUCA-15 was electroporated into human Jurkat acute T cell leukaemia clone E6 cells (ATCC No. TIB-152) as previously described (Sutherland et al., 2000; Sutherland and Williams, 1997) . Cells were grown in Iscoves's Modi®ed Dulbecco's medium containing 4 mM glutamine (Life Technologies) supplemented with 10% heat inactivated foetal bovine serum (Summit Biotechnology), at 378C in a 5% CO 2 humidi®ed incubator. Stable clones were selected in 1.0 mg/ml geneticin (Roche Molecular Biochemicals). (a) Three stably transfected vector alone clones and the six stably transfected LUCA-15 clones which survived selection were examined for their ability to resist cell death by growth in 1000 ng/ml IPO-4 anti-human CD95 antibody (Kamiya), for 5 and 24 h. (b) One vector alone clone (1.1) and the four LUCA-15 transfected clones with the greatest resistance to CD95-mediated apoptosis (3.1, 3.2, 3.3, 3.4) were then examined by immunoblotting with anti-PARP antibody (66401A: PharMingen, 1 : 500). Cleavage of the 116 kD PARP protein to an 85 kD polypeptide occurs in cells undergoing apoptosis Figure 1a ). The four LUCA-15 stable clones which demonstrated greatest resistance to cell death were further examined by immunoblotting, using anti-PARP antibody (Figure 1b) . In repeated experiments, Jurkat/pcDNA3.LUCA-15 Clone 3.4 had the greatest ability to suppress CD95-mediated cell death, thus this clone was selected for further detailed analysis.
The level of overexpression of LUCA-15 in stable clones was examined by Western blot analysis. Fifty micrograms of whole cell lysate from Jurkat/pcDNA3 Clone 1.1 and Jurkat/pcDNA3.LUCA-15 Clone 3.4 were loaded onto SDS-polyacrylamide gels. Following electrophoresis and transfer, the bands observed by ECL detection were quanti®ed by densitometry (Molecular Dynamics 100A), using Quantity One software (PDI/Bio-Rad). Averaging the results obtained from three separate experiments, standardized to tubulin loading controls, a twofold overexpression of LUCA-15 protein in Clone 3.4 was observed.
The eect of LUCA-15 overexpression on Jurkat cell growth rate was then examined. Jurkat/pcDNA3 Clone 1.1 and Jurkat/pcDNA3.LUCA-15 Clone 3.4 were grown for 4 days and the proliferation rate recorded, based on cell counting and Trypan blue exclusion (Figure 2a) . A marginal, though not statistically signi®cant, dierence in the rate of proliferation between Jurkat cells transfected with LUCA-15 and Jurkat cells transfected with empty vector, was consistently observed. To determine whether LUCA-15 is important in the regulation of apoptosis, clones were then cultured in the absence or presence of 500 ng/ml anti-CD95 (IPO-4) antibody for up to 24 h. Jurkat/pcDNA3.LUCA-15 Clone 3.4 demonstrated a clear resistance to cell death (Figure 2b ). Cells overexpressing LUCA-15 were 44% more viable after 5 h in anti-CD95 antibody than control cells, and 52% more viable after 24 h.
As resistance to CD95-mediated cell death could be due to loss of receptor expression, a phenomenon which could be unrelated to LUCA-15 expression, cells were analysed for surface CD95. Jurkat/pcDNA3 and Jurkat/pcDNA3.LUCA-15 stable clones were grown in medium containing serum, then washed and incubated with FITC-conjugated anti-CD95 antibody, or an isotype control. TF-1 cells, which do not express surface CD95, were used as a negative control. Greater than 94% of both Jurkat groups¯uoresced in the presence of anti-CD95 antibody (Figure 3) , and for this reason it was concluded that LUCA-15 overexpression does not signi®cantly alter surface CD95 expression. This result demonstrates that resistance to CD95-mediated apoptosis is unlikely to be due to loss of surface CD95 receptor, either as a result of spontaneous mutation or as a mechanism of action of LUCA-15, and suggests that LUCA-15 functions to suppress CD95-mediated apoptosis at a more distal point in the apoptotic pathway.
Apoptosis induced by CD95 crosslinking proceeds via at least two signalling cascades, depending on the quantity of caspase-8 recruited to the CD95-associated DISC complex (incorporating CD95, FADD and caspase-8) (Scadi et al., 1998) . When large quantities of caspase-8 are recruited, signalling proceeds independently of the mitochondria, and caspase-3 is cleaved directly. This pathway is not inhibitable by Bcl-2. However, when small quantities of caspase-8 are recruited to the DISC, signalling proceeds via a caspase cascade that involves the mitochondria. Which path- 5 cells/ml in complete medium containing 1.0 mg/ml geneticin, were treated with 500 ng/ml anti-CD95 antibody, and viability was determined after 5 and 24 h. The number of viable cells was determined by Trypan blue exclusion. Results are representative of three independent experiments, and cells used in the Western blot shown in Figure 4 were collected from the data points shown on this ®gure way is used appears to be a cell type-speci®c phenomenon; however, should one pathway be blocked, apoptosis may proceed via the alternate route. CD95-mediated apoptosis in Jurkat cells is predominantly a mitochondrial dependent pathway (Scadi et al., 1998) . Caspase-8 cleaves BID, which translocates to the mitochondrial membrane, thereby releasing Cytochrome c (Cc), a process inhibitable by Bcl-2 (Luo et al., 1998) . Cc then interacts with ATP, APAF-1 and caspase-9, inducing cleavage of caspase-9. Activated caspase-9 then cleaves caspase-3 and may cleave more caspase-8 Tang et al., 2000; Yoshida et al., 1998) . Activated caspase-3 is responsible for the cleavage of many proteins involved in the ®nal execution phase of apoptosis, including poly(ADP-ribose) polymerase (PARP); however, it has recently been shown that, in cytotoxic-drug-induced apoptosis, further BID cleavage occurs following caspase-3 activation (Slee et al., 2000; Tang et al., 2000) , thereby leading to an ampli®cation of the apoptotic stimulus.
Antibodies to various known components of the CD95-mediated apoptosis signalling pathway were used to probe a Western blot of whole cell extracts from Jurkat/pcDNA3 Clone 1.1 and Jurkat/pcDNA3.-LUCA-15 Clone 3.4 cells which had been exposed to anti-CD95-antibody for 0, 5 and 24 h. The apoptosis eectors caspase-8, BID, caspase-9, caspase-3 and PARP were examined for evidence of cleavage inhibition by LUCA-15. The inhibitors FLIP and Bcl-2 were examined for alteration in expression levels. Tubulin expression was examined as a loading control . As seen in Figure 4 , in the presence of anti-CD95 antibody cleavage of the most distal protein examined, PARP, was largely inhibited in the LUCA-15 overexpressing Clone 3.4. Working upstream of PARP in the CD95 signalling pathway, caspase-3 cleavage was suppressed, as was caspase-9 cleavage. From these results it is concluded that LUCA-15 functions to suppress CD95-mediated apoptosis prior to the execution stage of apoptosis. Expression of the apoptosis inhibitor Bcl-2 was elevated in the LUCA-15 overexpressing clone. In whole cell extracts taken from three individual experiments, at time 0 h, expression of Bcl-2 was on average threefold higher in the LUCA-15 overexpressing cells (by densitometric analysis). Notably, BID cleavage in the LUCA-15 overexpressing cells grown in the presence of anti-CD95 antibody was almost complete, indicating only marginal in¯uence of LUCA-15 overexpression at this stage. Minimal caspase-8 cleavage occurred in the LUCA-15 overexpressing cells in the presence of anti-CD95 antibody, as evidenced by the slightly reduced expression of the 55 kD polypeptide. Finally, expression of the inhibitor FLIP was unchanged. These results suggest a possible role for Bcl-2 in LUCA-15-mediated resistance to CD95-mediated apoptosis. Reduced cleavage of caspase-8 could be due to inhibition of the caspase-9/ caspase-8 cleavage feedback loop by up-regulated Bcl-2, ablating ampli®cation of the signal. In addition, although it has been suggested that caspase-3 is able to cleave BID in cytotoxic drug induced apoptosis, these results suggest that in Jurkat cells exposed to anti-CD95 antibody, where complete suppression of caspase-3 cleavage only slightly inhibits BID cleavage, caspase-3 does not cleave BID.
In order to determine the speci®city of LUCA-15 function to CD95-mediated apoptosis, and gain further insight into the mechanism of action of LUCA-15-induced resistance, the ability of LUCA-15 overexpression to suppress apoptosis mediated by staurosporine (STS), a protein kinase inhibitor 5 Jurkat, LUCA-15 transfected Jurkat, or TF-1 cells were washed with 500 ml cold phosphate buered saline (PBS) and resuspended in a total volume of 40 ml with 16PBS/1% bovine serum album (BSA). Cells were then immunostained with¯uorescein isothiocyanate (FITC)-conjugated mouse anti-human antibody IgG 1 , k (33814X: PharMingen) isotype control (20 ml/10 6 cells), or FITC-conjugated mouse anti-human CD95 IgG 1 antibody (33454X: PharMingen) (20 ml/10 6 cells), for 1 h on ice. The samples were washed twice in 150 ml 16PBS/0.1% BSA, once in 150 ml 16PBS, then resuspended in 500 ml 16PBS/0.1% sodium azide. Fluorescence intensity of surface bound antibody was analysed by FACScan (Becton Dickinson) using CellQuest software. The percentage of CD95 positive cells is indicated (Tamaoki et al., 1986) , and etoposide, a topoisomerase II inhibitor (Oshero, 1989) , was examined. Jurkat/ pcDNA3.LUCA-15 cells grown in the presence of 0.1 mM staurosporine demonstrated increased survival (Figure 5a ) (P=0.0309 in a one-way analysis of Figure 4 Western blot evidence of LUCA-15 suppression of CD95-mediated apoptosis. Each lane contains 50 mg of whole cell lysate, prepared as previously described (Sutherland et al., 2000) . Jurkat/pcDNA3 Clone 1.1 or Jurkat/pcDNA3.LUCA-15 Clone 3.4 cells were cultured+anti-CD95 antibody for 5 and 24 h. Protein was electrophoresed through either 10 or 15% polyacrylamide gels, and transferred to ImmunoBlot PVDF membrane (Bio-Rad). Blots were probed with rabbit anti-human LUCA-15 antibody (Sutherland et al., 2000) , used at a 1 : 2500 dilution, goat anti-human BID (sc-6538: Santa-Cruz, 1 : 100), hamster anti-human Bcl-2 (15131A: PharMingen, 1 : 2000), rabbit anti-human caspase-9 (sc-7885: Santa Cruz, 1 : 500), mouse antihuman caspase-8 (MAB704: R&D Systems, 1 : 1000), rabbit antihuman caspase-3 (556425: PharMingen, 1 : 1000), mouse antihuman PARP (66401A: PharMingen, 1 : 500), or mouse antihuman tubulin (8035: Santa Cruz, 1 : 2000) . Secondary antibodies used were HRP-conjugated donkey anti-rabbit Ig (NA934: Amersham, 1 : 2500), donkey anti-goat IgG (sc-2056: Santa Cruz, 1 : 5000), goat anti-Armenian hamster IgG (127-035-160: Jackson ImmunoResearch Labs, 1 : 2000) , sheep anti-mouse Ig (NA931: Amersham, 1 : 1500) or Protein A (NA9120: Amersham, 1 : 2000) . Protein A was used with the anti-caspase-9 antibody. Radiography was performed using an ECL chemiluminescence kit (Amersham). Per cent viability: the number of viable cells, as a percentage of control cells, determined by Trypan Blue exclusion (see Figure 2b) . The model outlined here shows the dominant CD95 signalling pathway (solid arrows) and two putative feedback loops (dashed arrows) Figure 5 LUCA-15 overexpression signi®cantly suppresses staurosporine-but not etoposide-induced cell death. Jurkat cells plated at 4610 5 cells/ml in complete medium containing 1.0 mg/ ml geneticin were treated with (a) 0.1 mM staurosporine (Sigma) or (b) 3.0 mg/ml etoposide (Calbiochem), at 378C for up to 31 h (the optimal concentration of each agent for inducing apoptosis in the Jurkat E6 cell clones was determined in preliminary experiments). The number of viable cells was determined by Trypan blue exclusion analysis. The mean values with standard deviation from three independent experiments, performed in triplicate, are shown. The absence of visible error bars on some data points indicates that the errors associated with the replicated experiments are within the range covered by the symbols variance of repeated measures between vector alone and LUCA-15), whereas those grown in the presence of 3 mg/ml etoposide did not demonstrate a signi®cant increase in cell viability (Figure 5b ) (P=0.257 in a oneway analysis of variance of repeated measures between vector alone and LUCA-15). These results indicate that LUCA-15 is not a general inhibitor of cell death.
The signalling pathways for both STS and etoposide are not yet well delineated, however studies have shown that Bcl-2 can totally inhibit etoposide-induced apoptosis (Dole et al., 1994; Kamesaki et al., 1993; Lock and Stribinskiene, 1996; Miyashita and Reed, 1993; Strasser et al., 1994) but only partially inhibit STS and CD95-mediated apoptosis (Johnson et al., 2000) . This suggests that, as for CD95, STS can regulate cell death via a mitochondrial-independent pathway. Suppression of one signalling pathway may lead to use of the other pathway. In this study it was observed that suppression of both CD95-and STSinduced cell death following 24 h exposure to the death-inducing agent, at the concentrations used, was approximately 52 and 36%, respectively, as determined by cell viability, indicating that LUCA-15 was unable to completely inhibit either apoptogenic stimulus. This could be due to limited overexpression of the transgene (only twofold), resulting in only partial suppression of the apoptotic pathway, but is also consistent with the use of an alternate pathway, thereby circumventing the block to cell death.
An important observation in these experiments is that LUCA-15 was unable to signi®cantly inhibit etoposide-induced apoptosis, a pathway which is inhibitable by Bcl-2. This strongly suggests that LUCA-15 does not suppress apoptosis solely, or directly, through up-regulation of Bcl-2 (as is suggested for CD95-mediated apoptosis in Jurkat cells), but via an additional factor which is involved in the transmission of both CD95-and STS-mediated apoptogenic signals, but not the etoposide-mediated signal. Most importantly, these results point to speci®city in the actions of LUCA-15 in opposing some, but not all, forms of apoptotic cell death. This in turn supports our observations that LUCA-15 operates distal to the initiation phase but proximal to the common execution phase of apoptosis.
The results of this study have important implications for both apoptosis regulation and cancer. LUCA-15 is located at an important site on chromosome 3 that is deleted in many small cell lung carcinoma cells (suggesting the presence of a tumour suppressor gene at this locus) but overexpressed in many breast cancer cells (suggesting that LUCA-15 may be an oncogene). The potentially dual role of this molecule as an apoptosis inhibitor and inducer might explain this dichotomy. Further studies are now underway to more clearly delineate the mechanism of action of LUCA-15, and its splice variants, in regulating apoptosis, and to explore the possible in¯uence of mutations and host cell type on the eects observed.
